Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration
Abstract
:Simple Summary
Abstract
1. Introduction
2. Epidermal Growth Factor (EGF)
3. Transforming Growth Factor α (TGFα)
4. Transforming Growth Factor β (TGFβ)
5. Vascular Endothelial Growth Factor (VEGF)
6. Nerve Growth Factor (NGF)
7. Discussion and Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Appendix A
Appendix A.1. Cell Lines
Appendix A.2. TYS
Appendix A.3. Wound Healing Assay
Appendix A.4. Scatter Assay
References
- Weijer, C.J. Collective cell migration in development. J. Cell Sci. 2009, 122, 3215–3223. [Google Scholar] [CrossRef] [Green Version]
- Geary, L.; LaBonne, C. FGF mediated MAPK and PI3K/Akt Signals make distinct contributions to pluripotency and the establishment of Neural Crest. Elife 2018, 7, e33845. [Google Scholar] [CrossRef]
- Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129, 1261–1274. [Google Scholar] [CrossRef] [Green Version]
- Clark, A.G.; Vignjevic, D.M. Modes of cancer cell invasion and the role of the microenvironment. Curr. Opin. Cell Biol. 2015, 36, 13–22. [Google Scholar] [CrossRef] [Green Version]
- Friedl, P.; Wolf, K. Proteolytic interstitial cell migration: A five-step process. Cancer Metastasis Rev. 2009, 28, 129–135. [Google Scholar] [CrossRef] [Green Version]
- Weiner, O.D. Regulation of cell polarity during eukaryotic chemotaxis: The chemotactic compass. Curr. Opin. Cell Biol. 2002, 14, 196–202. [Google Scholar] [CrossRef] [Green Version]
- Charest, P.G.; Firtel, R.A. Feedback signaling controls leading-edge formation during chemotaxis. Curr. Opin. Genet. Dev. 2006, 16, 339–347. [Google Scholar] [CrossRef]
- Ellis, I.R.; Jones, S.J.; Lindsay, Y.; Ohe, G.; Schor, A.M.; Schor, S.L.; Leslie, N.R. Migration Stimulating Factor (MSF) promotes fibroblast migration by inhibiting AKT. Cell. Signal. 2010, 22, 1655–1659. [Google Scholar] [CrossRef]
- Islam, M.R.; Jones, S.J.; Macluskey, M.; Ellis, I.R. Is there a pAkt between VEGF and oral cancer cell migration? Cell. Signal. 2014, 26, 1294–1302. [Google Scholar] [CrossRef]
- Ip, C.K.M.; Cheung, A.N.Y.; Ngan, H.Y.S.; Wong, A.S.T. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 2011, 30, 2420–2432. [Google Scholar] [CrossRef] [Green Version]
- Qian, Y.; Zhong, X.; Flynn, D.C.; Zheng, J.Z.; Qiao, M.; Wu, C.; Dedhar, S.; Shi, X.; Jiang, B.-H. ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling. Oncogene 2005, 24, 3154–3165. [Google Scholar] [CrossRef] [Green Version]
- Shibata, T.; Matsuo, Y.; Shamoto, T.; Hirokawa, T.; Tsuboi, K.; Takahashi, H.; Ishiguro, H.; Kimura, M.; Takeyama, H.; Inagaki, H. Girdin, a regulator of cell motility, is a potential prognostic marker for esophageal squamous cell carcinoma. Oncol. Rep. 2013, 29, 2127–2132. [Google Scholar] [CrossRef] [Green Version]
- Wang, W.; Chen, H.; Gao, W.; Wang, S.; Wu, K.; Lu, C.; Luo, X.; Li, L.; Yu, C. Girdin interaction with vimentin induces EMT and promotes the growth and metastasis of pancreatic ductal adenocarcinoma. Oncol. Rep. 2020, 44, 637–649. [Google Scholar] [CrossRef]
- Xue, G.; Restuccia, D.F.; Lan, Q.; Hynx, D.; Dirnhofer, S.; Hess, D.; Rüegg, C.; Hemmings, B.A. Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-β Signaling Axes. Cancer Discov. 2012, 2, 248–259. [Google Scholar] [CrossRef] [Green Version]
- Soriano, O.; Alcón-Pérez, M.; Vicente-Manzanares, M.; Castellano, E. The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction. Genes 2021, 12, 819. [Google Scholar] [CrossRef]
- Ilina, O.; Friedl, P. Mechanisms of collective cell migration at a glance. J. Cell Sci. 2009, 122, 3203–3208. [Google Scholar] [CrossRef] [Green Version]
- Mayor, R.; Etienne-Manneville, S. The front and rear of collective cell migration. Nat. Rev. Mol. Cell Biol. 2016, 17, 97–109. [Google Scholar] [CrossRef] [Green Version]
- Langley, R.R.; Fidler, I.J. The seed and soil hypothesis revisited—The role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 2011, 128, 2527–2535. [Google Scholar] [CrossRef] [Green Version]
- Nallanthighal, S.; Heiserman, J.P.; Cheon, D.-J. The Role of the Extracellular Matrix in Cancer Stemness. Front. Cell Dev. Biol. 2019, 7, 86. [Google Scholar] [CrossRef]
- Johnson, D.E.; Burtness, B.; Leemans, C.R.; Lui, V.W.Y.; Bauman, J.E.; Grandis, J.R. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Primers 2020, 6, 92. [Google Scholar] [CrossRef]
- Ellis, I.R. The Migration and Invasion of Oral Squamous Carcinoma Cells: Matrix, Growth Factor and Signalling Involvement. Cancers 2021, 13, 2633. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [Green Version]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Yuan, Y.; Jiang, Y.-C.; Sun, C.-K.; Chen, Q.-M. Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol. Rep. 2016, 35, 2499–2515. [Google Scholar] [CrossRef] [Green Version]
- Cohen, S. Origins of growth factors: NGF and EGF. Ann. N. Y. Acad. Sci. 2004, 1038, 98–102. [Google Scholar] [CrossRef] [Green Version]
- Carpenter, G.; Cohen, S. Epidermal growth factor. J. Biol. Chem. 1990, 265, 7709–7712. [Google Scholar] [CrossRef]
- NobelPrize.org. The Nobel Prize in Physiology or Medicine. 1986. Available online: https://www.nobelprize.org/prizes/medicine/1986/summary/ (accessed on 2 December 2021).
- Zhang, X.; Nie, D.; Chakrabarty, S. Growth factors in tumor microenvironment. Front Biosci. 2010, 15, 151–165. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.; Dong, Z.; Lauxen, I.S.; Filho, M.S.; Nör, J.E. Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res. 2014, 74, 2869–2881. [Google Scholar] [CrossRef] [Green Version]
- Castaño, Z.; Marsh, T.; Tadipatri, R.; Kuznetsov, H.S.; Al-Shahrour, F.; Paktinat, M.; Greene-Colozzi, A.; Nilsson, B.; Richardson, A.L.; McAllister, S.S. Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov. 2013, 3, 922–935. [Google Scholar] [CrossRef] [Green Version]
- Cardoso, A.P.; Pinto, M.L.; Pinto, A.T.; Oliveira, M.I.; Pinto, M.T.; Gonçalves, R.; Relvas, J.B.; Figueiredo, C.; Seruca, R.; Mantovani, A.; et al. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity. Oncogene 2014, 33, 2123–2133. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Liao, D.; Chen, C.; Liu, Y.; Chuang, T.H.; Xiang, R.; Markowitz, D.; Reisfeld, R.A.; Luo, Y. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem. Cells 2013, 31, 248–258. [Google Scholar] [CrossRef]
- Normanno, N.; Gullick, W.J. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: Different mechanisms of action for a novel therapeutic application? Endocr. Relat. Cancer 2006, 13, 3–6. [Google Scholar] [CrossRef] [Green Version]
- Baselga, J.; Arteaga, C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23, 2445–2459. [Google Scholar] [CrossRef]
- Yarden, Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37 (Suppl. S4), S3–S8. [Google Scholar] [CrossRef]
- Franovic, A.; Gunaratnam, L.; Smith, K.; Robert, I.; Patten, D.; Lee, S. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 13092–13097. [Google Scholar] [CrossRef] [Green Version]
- Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366, 2–16. [Google Scholar] [CrossRef]
- Chan, D.A.; Giaccia, A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007, 26, 333–339. [Google Scholar] [CrossRef]
- Lunt, S.J.; Chaudary, N.; Hill, R.P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 2009, 26, 19–34. [Google Scholar] [CrossRef]
- Goldoni, S.; Iozzo, R.V. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int. J. Cancer 2008, 123, 2473–2479. [Google Scholar] [CrossRef]
- Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.; Ward, C.W.; Burgess, A.W. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp. Cell Res. 2003, 284, 31–53. [Google Scholar] [CrossRef]
- Laimer, K.; Spizzo, G.; Gastl, G.; Obrist, P.; Brunhuber, T.; Fong, D.; Barbieri, V.; Jank, S.; Doppler, W.; Rasse, M.; et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. Oral Oncol. 2007, 43, 193–198. [Google Scholar] [CrossRef] [PubMed]
- Bonner, J.A.; Harari, P.M.; Giralt, J.; Cohen, R.B.; Jones, C.U.; Sur, R.K.; Raben, D.; Baselga, J.; Spencer, S.A.; Zhu, J.; et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010, 11, 21–28. [Google Scholar] [CrossRef]
- Fung, C.; Grandis, J.R. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin. Emerg. Drugs 2010, 15, 355–373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ulanovski, D.; Stern, Y.; Roizman, P.; Shpitzer, T.; Popovtzer, A.; Feinmesser, R. Expression of EGFR and Cerb-B2 as prognostic factors in cancer of the tongue. Oral Oncol. 2004, 40, 532–537. [Google Scholar] [CrossRef]
- Yamada, T.; Takagi, M.; Shioda, S. Evaluation of epidermal growth factor receptor in squamous cell carcinoma of the oral cavity. Oral Surg. Oral Med. Oral Pathol. 1992, 73, 67–70. [Google Scholar] [CrossRef]
- Chang, K.-Y.; Tsai, S.-Y.; Chen, S.-H.; Tsou, H.-H.; Yen, C.-J.; Liu, K.-J.; Fang, H.-L.; Wu, H.-C.; Chuang, B.-F.; Chou, S.-W.; et al. Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. J. Biomed. Sci. 2013, 20, 43. [Google Scholar] [CrossRef] [Green Version]
- Temam, S.; Kawaguchi, H.; El-Naggar, A.K.; Jelinek, J.; Tang, H.; Liu, D.D.; Lang, W.; Issa, J.-P.; Lee, J.J.; Mao, L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 2007, 25, 2164–2170. [Google Scholar] [CrossRef]
- Modjtahedi, H.; Essapen, S. Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities. Anti-Cancer Drugs 2009, 20, 851–855. [Google Scholar] [CrossRef]
- Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505–516. [Google Scholar] [CrossRef]
- Kalyankrishna, S.; Grandis, J.R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 2006, 24, 2666–2672. [Google Scholar] [CrossRef]
- Huang, C.; Jacobson, K.; Schaller, M.D. MAP kinases and cell migration. J. Cell Sci. 2004, 117, 4619–4628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bunney, T.D.; Katan, M. Phosphoinositide signalling in cancer: Beyond PI3K and PTEN. Nat. Rev. Cancer 2010, 10, 342–352. [Google Scholar] [CrossRef] [PubMed]
- Kölsch, V.; Charest, P.G.; Firtel, R.A. The regulation of cell motility and chemotaxis by phospholipid signaling. J. Cell Sci. 2008, 121, 551–559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Irie, H.Y.; Pearline, R.V.; Grueneberg, D.; Hsia, M.; Ravichandran, P.; Kothari, N.; Natesan, S.; Brugge, J.S. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J. Cell Biol. 2005, 171, 1023–1034. [Google Scholar] [CrossRef] [PubMed]
- Loesch, M.; Chen, G. The p38 MAPK stress pathway as a tumor suppressor or more? Front Biosci. 2008, 13, 3581–3593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ye, M.; Hu, D.; Tu, L.; Zhou, X.; Lu, F.; Wen, B.; Wu, W.; Lin, Y.; Zhou, Z.; Qu, J. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Investig. Ophthalmol. Vis. Sci. 2008, 49, 497–504. [Google Scholar] [CrossRef]
- Jiang, N.; Dai, Q.; Su, X.; Fu, J.; Feng, X.; Peng, J. Role of PI3K/AKT pathway in cancer: The framework of malignant behavior. Mol. Biol. Rep. 2020, 47, 4587–4629. [Google Scholar] [CrossRef]
- Lim, J.; Kim, J.H.; Paeng, J.Y.; Kim, M.J.; Hong, S.D.; Lee, J.I.; Hong, S.P. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J. Clin. Pathol. 2005, 58, 1199. [Google Scholar] [CrossRef] [Green Version]
- Song, M.; Bode, A.M.; Dong, Z.; Lee, M.-H. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019, 79, 1019. [Google Scholar] [CrossRef] [Green Version]
- Islam, M.; Mane, S.; Hyder, E.; Jones, S.; Ellis, I. The motogenic effect of EGF and TGF-α on the migration of tumor cells from the oral region: A role of epithelial-to-mesenchymal transition in cancer and a route for translation into the clinic. Transl. Res. Oral Oncol. 2017, 2, 2057178X17698481. [Google Scholar] [CrossRef] [Green Version]
- Ford, A.C.; Grandis, J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25, 67–73. [Google Scholar] [CrossRef] [PubMed]
- Muthusami, S.; Prabakaran, D.S.; Yu, J.R.; Park, W.Y. EGF-induced expression of Fused Toes Homolog (FTS) facilitates epithelial-mesenchymal transition and promotes cell migration in ME180 cervical cancer cells. Cancer Lett. 2014, 351, 252–259. [Google Scholar] [CrossRef] [PubMed]
- Xu, Q.; Zhang, Q.; Ishida, Y.; Hajjar, S.; Tang, X.; Shi, H.; Dang, C.V.; Le, A.D. EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. Oncotarget 2017, 8, 9557–9571. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Lin, Z.; Sun, L.; Fan, S.; Huang, Z.; Zhang, D.; Yang, Z.; Li, J.; Chen, W. Akt/Ezrin Tyr353/NF-κB pathway regulates EGF-induced EMT and metastasis in tongue squamous cell carcinoma. Br. J. Cancer 2014, 110, 695–705. [Google Scholar] [CrossRef]
- De Larco, J.E.; Todaro, G.J. Sarcoma growth factor (SGF): Specific binding to epidermal growth factor (EGF) membrane receptors. J. Cell Physiol. 1980, 102, 267–277. [Google Scholar] [CrossRef] [PubMed]
- Kubiczkova, L.; Sedlarikova, L.; Hajek, R.; Sevcikova, S. TGF-β—An excellent servant but a bad master. J. Transl. Med. 2012, 10, 183. [Google Scholar] [CrossRef] [Green Version]
- Ebner, R.; Derynck, R. Epidermal growth factor and transforming growth factor-alpha: Differential intracellular routing and processing of ligand-receptor complexes. Cell Regul. 1991, 2, 599–612. [Google Scholar] [CrossRef] [Green Version]
- Derynck, R. Transforming growth factor-alpha. Mol. Reprod. Dev. 1990, 27, 3–9. [Google Scholar] [CrossRef]
- Hsuan, J.J. Transforming Growth Factor (TGF) Alpha. In Encyclopedia of Endocrine Diseases; Martini, L., Ed.; Elsevier: New York, NY, USA, 2004; pp. 605–611. [Google Scholar] [CrossRef]
- Rappolee Daniel, A.; Mark, D.; Banda Michael, J.; Werb, Z. Wound Macrophages Express TGF-α and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping. Science 1988, 241, 708–712. [Google Scholar] [CrossRef]
- Winkler, M.E.; O’Connor, L.; Winget, M.; Fendly, B. Epidermal growth factor and transforming growth factor alpha bind differently to the epidermal growth factor receptor. Biochemistry 1989, 28, 6373–6378. [Google Scholar] [CrossRef]
- Schreiber, A.B.; Winkler, M.E.; Derynck, R. Transforming growth factor-alpha: A more potent angiogenic mediator than epidermal growth factor. Science 1986, 232, 1250–1253. [Google Scholar] [CrossRef] [PubMed]
- Grandis, J.; Melhem, M.F.; Barnes, E.L.; Tweardy, D.J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996, 78, 1284–1292. [Google Scholar] [CrossRef]
- Grandis, J.; Melhem, M.F.; Gooding, W.E.; Day, R.; Holst, V.A.; Wagener, M.M.; Drenning, S.D.; Tweardy, D.J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 1998, 90, 824–832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grandis, J.R.; Tweardy, D.J. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993, 53, 3579–3584. [Google Scholar] [PubMed]
- Grandis, J.; Chakraborty, A.; Melhem, M.F.; Zeng, Q.; Tweardy, D.J. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997, 15, 409–416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Endo, S.; Zeng, Q.; Burke, N.A.; He, Y.; Melhem, M.F.; Watkins, S.F.; Lango, M.N.; Drenning, S.D.; Huang, L.; Rubin Grandis, J. TGF-α antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo. Gene Ther. 2000, 7, 1906–1914. [Google Scholar] [CrossRef] [Green Version]
- Fasano, M.; Della Corte, C.M.; Viscardi, G.; Di Liello, R.; Paragliola, F.; Sparano, F.; Iacovino, M.L.; Castrichino, A.; Doria, F.; Sica, A.; et al. Head and neck cancer: The role of anti-EGFR agents in the era of immunotherapy. Ther. Adv. Med. Oncol. 2021, 13, 1758835920949418. [Google Scholar] [CrossRef]
- Psyrri, A.; Seiwert, T.Y.; Jimeno, A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am. Soc. Clin. Oncol. Educ. Book 2013, 33, 246–255. [Google Scholar] [CrossRef]
- Roberts, A.B.; Sporn, M.B.; Assoian, R.K.; Smith, J.M.; Roche, N.S.; Wakefield, L.M.; Heine, U.I.; Liotta, L.A.; Falanga, V.; Kehrl, J.H.; et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA 1986, 83, 4167–4171. [Google Scholar] [CrossRef] [Green Version]
- Massagué, J.; Blain, S.W.; Lo, R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103, 295–309. [Google Scholar] [CrossRef] [Green Version]
- Patterson, G.I.; Padgett, R.W. TGF beta-related pathways. Roles in Caenorhabditis elegans development. Trends Genet. 2000, 16, 27–33. [Google Scholar] [CrossRef]
- Roberts, A.B.; Anzano, M.A.; Wakefield, L.M.; Roche, N.S.; Stern, D.F.; Sporn, M.B. Type beta transforming growth factor: A bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA 1985, 82, 119–123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tucker, R.F.; Shipley, G.D.; Moses, H.L.; Holley, R.W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 1984, 226, 705–707. [Google Scholar] [CrossRef] [PubMed]
- Pickup, M.; Novitskiy, S.; Moses, H.L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 2013, 13, 788–799. [Google Scholar] [CrossRef] [Green Version]
- Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577–584. [Google Scholar] [CrossRef]
- Papageorgis, P.; Stylianopoulos, T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int. J. Oncol. 2015, 46, 933–943. [Google Scholar] [CrossRef] [Green Version]
- Hazelbag, S.; Gorter, A.; Kenter, G.G.; van den Broek, L.; Fleuren, G. Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum. Pathol. 2002, 33, 1193–1199. [Google Scholar] [CrossRef]
- Walker, R.A.; Dearing, S.J.; Gallacher, B. Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br. J. Cancer 1994, 69, 1160–1165. [Google Scholar] [CrossRef] [Green Version]
- Wikström, P.; Stattin, P.; Franck-Lissbrant, I.; Damber, J.E.; Bergh, A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37, 19–29. [Google Scholar] [CrossRef]
- Dalal, B.I.; Keown, P.A.; Greenberg, A.H. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am. J. Pathol. 1993, 143, 381–389. [Google Scholar]
- Gascard, P.; Tlsty, T.D. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev. 2016, 30, 1002–1019. [Google Scholar] [CrossRef] [PubMed]
- Wipff, P.J.; Rifkin, D.B.; Meister, J.J.; Hinz, B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 2007, 179, 1311–1323. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karagiannis, G.S.; Poutahidis, T.; Erdman, S.E.; Kirsch, R.; Riddell, R.H.; Diamandis, E.P. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol. Cancer Res. MCR 2012, 10, 1403–1418. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tomasek, J.J.; Gabbiani, G.; Hinz, B.; Chaponnier, C.; Brown, R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3, 349–363. [Google Scholar] [CrossRef] [PubMed]
- Levy, L.; Hill, C.S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006, 17, 41–58. [Google Scholar] [CrossRef]
- Lu, S.L.; Reh, D.; Li, A.G.; Woods, J.; Corless, C.L.; Kulesz-Martin, M.; Wang, X.J. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004, 64, 4405–4410. [Google Scholar] [CrossRef] [Green Version]
- Qiao, B.; Johnson, N.W.; Gao, J. Epithelial-mesenchymal transition in oral squamous cell carcinoma triggered by transforming growth factor-beta1 is Snail family-dependent and correlates with matrix metalloproteinase-2 and -9 expressions. Int. J. Oncol. 2010, 37, 663–668. [Google Scholar] [CrossRef]
- Smith, A.; Teknos, T.N.; Pan, Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013, 49, 287–292. [Google Scholar] [CrossRef] [Green Version]
- Richter, P.; Umbreit, C.; Franz, M.; Berndt, A.; Grimm, S.; Uecker, A.; Böhmer, F.D.; Kosmehl, H.; Berndt, A. EGF/TGFβ1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J. Oral Pathol. Med. 2011, 40, 46–54. [Google Scholar] [CrossRef]
- Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moeendarbary, E.; Charras, G.; et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 2013, 15, 637–646. [Google Scholar] [CrossRef]
- Ahmed, H.; Ghoshal, A.; Jones, S.; Ellis, I.; Islam, M. Head and Neck Cancer Metastasis and the Effect of the Local Soluble Factors, from the Microenvironment, on Signalling Pathways: Is It All about the Akt? Cancers 2020, 12, 2093. [Google Scholar] [CrossRef] [PubMed]
- Li, K.; Yang, L.; Li, J.; Guan, C.; Zhang, S.; Lao, X.; Ouyang, D.; Zheng, G.; Gao, S.; Wang, D.; et al. TGFβ induces stemness through non-canonical AKT-FOXO3a axis in oral squamous cell carcinoma. EBioMedicine 2019, 48, 70–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Folkman, J.; Merler, E.; Abernathy, C.; Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 1971, 133, 275–288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983–985. [Google Scholar] [CrossRef]
- Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161, 851–858. [Google Scholar] [CrossRef]
- Sunderkötter, C.; Steinbrink, K.; Goebeler, M.; Bhardwaj, R.; Sorg, C. Macrophages and angiogenesis. J. Leukoc. Biol. 1994, 55, 410–422. [Google Scholar] [CrossRef] [PubMed]
- Verheul, H.M.; Hoekman, K.; Luykx-de Bakker, S.; Eekman, C.A.; Folman, C.C.; Broxterman, H.J.; Pinedo, H.M. Platelet: Transporter of vascular endothelial growth factor. Clin. Cancer Res. 1997, 3, 2187–2190. [Google Scholar]
- Frank, S.; Hübner, G.; Breier, G.; Longaker, M.T.; Greenhalgh, D.G.; Werner, S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 1995, 270, 12607–12613. [Google Scholar] [CrossRef] [Green Version]
- Iijima, K.; Yoshikawa, N.; Connolly, D.T.; Nakamura, H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int. 1993, 44, 959–966. [Google Scholar] [CrossRef] [Green Version]
- Boocock, C.A.; Charnock-Jones, D.S.; Sharkey, A.M.; McLaren, J.; Barker, P.J.; Wright, K.A.; Twentyman, P.R.; Smith, S.K. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J. Natl. Cancer Inst. 1995, 87, 506–516. [Google Scholar] [CrossRef]
- Itakura, J.; Ishiwata, T.; Shen, B.; Kornmann, M.; Korc, M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 2000, 85, 27–34. [Google Scholar] [CrossRef]
- Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer 2011, 2, 1097–1105. [Google Scholar] [CrossRef] [PubMed]
- Bergers, G.; Brekken, R.; McMahon, G.; Vu, T.H.; Itoh, T.; Tamaki, K.; Tanzawa, K.; Thorpe, P.; Itohara, S.; Werb, Z.; et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2, 737–744. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.T.; Luque, A.; Lee, S.; Anderson, S.M.; Segura, T.; Iruela-Arispe, M.L. Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J. Cell Biol. 2010, 188, 595–609. [Google Scholar] [CrossRef] [Green Version]
- Kowanetz, M.; Ferrara, N. Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective. Clin. Cancer Res. 2006, 12, 5018. [Google Scholar] [CrossRef] [Green Version]
- Mittal, K.; Koon, H.; Elson, P.; Triozzi, P.; Dowlati, A.; Chen, H.; Borden, E.C.; Rini, B.I. Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers. Cancer Biol. Ther. 2014, 15, 975–981. [Google Scholar] [CrossRef]
- Mărgăritescu, C.; Pirici, D.; Simionescu, C.; Mogoantă, L.; Raica, M.; Stîngă, A.; Ciurea, R.; Stepan, A.; Stîngă, A.; Ribatti, D. VEGF and VEGFRs expression in oral squamous cell carcinoma. Rom. J. Morphol. Embryol. 2009, 50, 527–548. [Google Scholar]
- Joo, Y.H.; Jung, C.K.; Kim, M.S.; Sun, D.I. Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer. Otolaryngol. Head Neck Surg. 2009, 140, 512–518. [Google Scholar] [CrossRef]
- Kim, S.H.; Cho, N.H.; Kim, K.; Lee, J.S.; Koo, B.S.; Kim, J.H.; Chang, J.H.; Choi, E.C. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J. Surg. Oncol. 2006, 93, 330–337. [Google Scholar] [CrossRef]
- Shao, Z.; Zhang, W.F.; Chen, X.M.; Shang, Z.J. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: Correlation with the angiogenesis and clinical outcome. Oral Oncol. 2008, 44, 1110–1117. [Google Scholar] [CrossRef]
- Islam, M.R.; Ellis, I.R.; Macluskey, M.; Cochrane, L.; Jones, S.J. Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: Is there evidence to support a prognostic or diagnostic role? Exp. Hematol. Oncol. 2014, 3, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levi-Montalcini, R.; Hamburger, V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 1951, 116, 321–361. [Google Scholar] [CrossRef] [PubMed]
- Aloe, L.; Rocco, M.L.; Bianchi, P.; Manni, L. Nerve growth factor: From the early discoveries to the potential clinical use. J. Transl. Med. 2012, 10, 239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Levi-Montalcini, R. The nerve growth factor. Ann. N. Y. Acad. Sci. 1964, 118, 149–170. [Google Scholar] [CrossRef] [PubMed]
- Apfel, S.C.; Arezzo, J.C.; Brownlee, M.; Federoff, H.; Kessler, J.A. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994, 634, 7–12. [Google Scholar] [CrossRef]
- Tessarollo, L. Pleiotropic functions of neurotrophins in development. Cytokine Growth Factor Rev. 1998, 9, 125–137. [Google Scholar] [CrossRef]
- Ferreira, D.; Westman, E.; Eyjolfsdottir, H.; Almqvist, P.; Lind, G.; Linderoth, B.; Seiger, A.; Blennow, K.; Karami, A.; Darreh-Shori, T.; et al. Brain changes in Alzheimer’s disease patients with implanted encapsulated cells releasing nerve growth factor. J. Alzheimers Dis. 2015, 43, 1059–1072. [Google Scholar] [CrossRef]
- Lambiase, A.; Aloe, L.; Centofanti, M.; Parisi, V.; Mantelli, F.; Colafrancesco, V.; Manni, G.L.; Bucci, M.G.; Bonini, S.; Levi-Montalcini, R. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc. Natl. Acad. Sci. USA 2009, 106, 13469. [Google Scholar] [CrossRef] [Green Version]
- Krüttgen, A.; Schneider, I.; Weis, J. The dark side of the NGF family: Neurotrophins in neoplasias. Brain Pathol. 2006, 16, 304–310. [Google Scholar] [CrossRef]
- Schecterson, L.C.; Bothwell, M. Neurotrophin receptors: Old friends with new partners. Dev. Neurobiol. 2010, 70, 332–338. [Google Scholar] [CrossRef]
- Alkhadar, H.; Macluskey, M.; White, S.; Ellis, I. Perineural invasion in oral squamous cell carcinoma: Incidence, prognostic impact and molecular insight. J. Oral Pathol. Med. 2020, 49, 994–1003. [Google Scholar] [CrossRef] [PubMed]
- Kolokythas, A.; Cox, D.P.; Dekker, N.; Schmidt, B.L. Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: Is there an association with perineural invasion? J. Oral Maxillofac. Surg. 2010, 68, 1290–1295. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Sun, M.; Jiang, Y.; Yang, L.; Lei, D.; Lu, C.; Zhao, Y.; Zhang, P.; Yang, Y.; Li, J. Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: Expression patterns and effects on in vitro invasive behavior. J. Oral Maxillofac. Surg. 2006, 64, 636–641. [Google Scholar] [CrossRef] [PubMed]
- Shen, W.R.; Wang, Y.P.; Chang, J.Y.; Yu, S.Y.; Chen, H.M.; Chiang, C.P. Perineural invasion and expression of nerve growth factor can predict the progression and prognosis of oral tongue squamous cell carcinoma. J. Oral Pathol. Med. 2014, 43, 258–264. [Google Scholar] [CrossRef] [PubMed]
- Hao, L.; Xiao-lin, N.; Qi, C.; Yi-ping, Y.; Jia-quan, L.; Yan-ning, L. Nerve growth factor and vascular endothelial growth factor: Retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int. J. Oral Sci. 2010, 2, 35–44. [Google Scholar] [CrossRef] [PubMed]
- Ye, Y.; Dang, D.; Zhang, J.; Viet, C.T.; Lam, D.K.; Dolan, J.C.; Gibbs, J.L.; Schmidt, B.L. Nerve growth factor links oral cancer progression, pain, and cachexia. Mol. Cancer Ther. 2011, 10, 1667–1676. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Søland, T.M.; Brusevold, I.J.; Koppang, H.S.; Schenck, K.; Bryne, M. Nerve growth factor receptor (p75 NTR) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma. Histopathology 2008, 53, 62–72. [Google Scholar] [CrossRef] [PubMed]
- Alkhadar, H.; Macluskey, M.; White, S.; Ellis, I. Nerve growth factor-induced migration in oral and salivary gland tumour cells utilises the PI3K/Akt signalling pathway: Is there a link to perineural invasion? J. Oral Pathol. Med. 2020, 49, 227–234. [Google Scholar] [CrossRef]
- Khattri, A.; Sheikh, N.; Acharya, R.; Tan, Y.-H.C.; Kochanny, S.; Lingen, M.W.; Vokes, E.E.; Seiwert, T.Y. Mechanism of acquired resistance to cetuximab in head and neck cancer. J. Clin. Oncol. 2018, 36, e18061. [Google Scholar] [CrossRef]
- Montagut, C.; Dalmases, A.; Bellosillo, B.; Crespo, M.; Pairet, S.; Iglesias, M.; Salido, M.; Gallen, M.; Marsters, S.; Tsai, S.P.; et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18, 221–223. [Google Scholar] [CrossRef]
- Zaryouh, H.; De Pauw, I.; Baysal, H.; Pauwels, P.; Peeters, M.; Vermorken, J.B.; Lardon, F.; Wouters, A. The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy. Front. Oncol. 2021, 11, 3658. [Google Scholar] [CrossRef] [PubMed]
- Institute, N.C. Akt Inhibitor MK2206 in Treating Patients with Recurrent or Metastatic Head and Neck Cancer. Available online: https://ClinicalTrials.gov/show/NCT01349933 (accessed on 4 April 2022).
- Ma, B.B.Y.; Goh, B.C.; Lim, W.T.; Hui, E.P.; Tan, E.H.; Lopes, G.d.L.; Lo, K.W.; Li, L.; Loong, H.; Foster, N.R.; et al. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Investig. N. Drugs 2015, 33, 985–991. [Google Scholar] [CrossRef] [PubMed]
- Ho, A.L.; Foster, N.R.; Meyers, J.P.; Vasudeva, S.D.; Katabi, N.; Antonescu, C.R.; Pfister, D.G.; Horvath, L.E.; Erlichman, C.; Schwartz, G.K. Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma. J. Clin. Oncol. 2015, 33, 6039. [Google Scholar] [CrossRef]
- Institute, N.C. Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer. Available online: https://ClinicalTrials.gov/show/NCT05172245 (accessed on 4 April 2022).
- Chicago, U.O.; Institute, N.C. PI3K Inhibitor BKM120 and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Cancer. Available online: https://ClinicalTrials.gov/show/NCT01816984 (accessed on 19 May 2022).
- Cao, Z.; Liao, Q.; Su, M.; Huang, K.; Jin, J.; Cao, D. AKT and ERK dual inhibitors: The way forward? Cancer Lett. 2019, 459, 30–40. [Google Scholar] [CrossRef] [PubMed]
- Pacold, M.E.; Suire, S.; Perisic, O.; Lara-Gonzalez, S.; Davis, C.T.; Walker, E.H.; Hawkins, P.T.; Stephens, L.; Eccleston, J.F.; Williams, R.L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103, 931–943. [Google Scholar] [CrossRef] [Green Version]
- Guan, K.L.; Figueroa, C.; Brtva, T.R.; Zhu, T.; Taylor, J.; Barber, T.D.; Vojtek, A.B. Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 2000, 275, 27354–27359. [Google Scholar] [CrossRef]
- Guo, X.; Wang, X.-F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009, 19, 71–88. [Google Scholar] [CrossRef]
- Thwe, A.M.; Mossey, P.; Ellis, I.R. Effect of tyrosine kinase inhibitors on cell migration and epithelial-to-mesenchymal transition in Asian head and neck cancer cell lines. J. Oral Pathol. Med. 2021, 50, 1031–1039. [Google Scholar] [CrossRef]
- Teng, Y.; Gao, L.; Loveless, R.; Rodrigo, J.P.; Strojan, P.; Willems, S.M.; Nathan, C.-A.; Mäkitie, A.A.; Saba, N.F.; Ferlito, A. The Hidden Link of Exosomes to Head and Neck Cancer. Cancers 2021, 13, 5802. [Google Scholar] [CrossRef]
- Bussink, J.; van der Kogel, A.J.; Kaanders, J.H.A.M. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9, 288–296. [Google Scholar] [CrossRef]
- Mutschelknaus, L.; Azimzadeh, O.; Heider, T.; Winkler, K.; Vetter, M.; Kell, R.; Tapio, S.; Merl-Pham, J.; Huber, S.M.; Edalat, L.; et al. Radiation alters the cargo of exosomes released from squamous head and neck cancer cells to promote migration of recipient cells. Sci. Rep. 2017, 7, 12423. [Google Scholar] [CrossRef] [PubMed]
- Kim, E.H.; Suresh, M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. 2013, 4, 20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crompton, J.G.; Sukumar, M.; Roychoudhuri, R.; Clever, D.; Gros, A.; Eil, R.L.; Tran, E.; Hanada, K.; Yu, Z.; Palmer, D.C.; et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res. 2015, 75, 296–305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van der Waart, A.B.; van de Weem, N.M.P.; Maas, F.; Kramer, C.S.M.; Kester, M.G.D.; Falkenburg, J.H.F.; Schaap, N.; Jansen, J.H.; van der Voort, R.; Gattinoni, L.; et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 2014, 124, 3490–3500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Urak, R.; Walter, M.; Lim, L.; Wong, C.W.; Budde, L.E.; Thomas, S.; Forman, S.J.; Wang, X. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J. Immunother. Cancer 2017, 5, 26. [Google Scholar] [CrossRef] [Green Version]
- Li, Z.W.; Dalton, W.S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 2006, 20, 333–342. [Google Scholar] [CrossRef]
- Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv. Pharm. Bull. 2017, 7, 339–348. [Google Scholar] [CrossRef]
- Yanagawa, T.; Hayashi, Y.; Yoshida, H.; Yura, Y.; Nagamine, S.; Bando, T.; Sato, M. An adenoid squamous carcinoma-forming cell line established from an oral keratinizing squamous cell carcinoma expressing carcinoembryonic antigen. Am. J. Pathol. 1986, 124, 496–509. [Google Scholar]
- Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650–1659. [Google Scholar] [CrossRef]
- Chen, H.-C. Cell-Scatter Assay. In Cell Migration: Developmental Methods and Protocols; Guan, J.-L., Ed.; Humana Press: Totowa, NJ, USA, 2005; pp. 69–77. [Google Scholar] [CrossRef]
Trial Identifier | Phase | Stage of Cancer | Name of the Inhibitor | Combination | Status | Result | Ref. |
---|---|---|---|---|---|---|---|
NCT01349933 | II | Stage IV/recurrent NPC | MK2206 | None | Completed | CR–0% PR-4.8% Stable disease-52.4% | [144] |
NCT01370070 | II | Recurrent NPC | MK2206 | None | Completed | CR–0% PR-5%, Stable disease-52% | [145] |
NCT01604772 | II | Recurrent/stage IV ADCC | MK2206 | None | Completed | CR/PR–0% Stable disease-81% | [146] |
NCT05172245 | I | Stage III-IVB HNSCC | Ipatasertib | Cisplatin /Radiation | Not yet recruiting | – | [147] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alzawi, A.; Iftikhar, A.; Shalgm, B.; Jones, S.; Ellis, I.; Islam, M. Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration. Cancers 2022, 14, 2606. https://doi.org/10.3390/cancers14112606
Alzawi A, Iftikhar A, Shalgm B, Jones S, Ellis I, Islam M. Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration. Cancers. 2022; 14(11):2606. https://doi.org/10.3390/cancers14112606
Chicago/Turabian StyleAlzawi, Albashir, Anem Iftikhar, Basher Shalgm, Sarah Jones, Ian Ellis, and Mohammad Islam. 2022. "Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration" Cancers 14, no. 11: 2606. https://doi.org/10.3390/cancers14112606